iBreastExam

What iBreastExam does

iBreastExam is a medical device brand developed by UE LifeSciences Inc., a privately held company headquartered in Philadelphia with operations in India and Malaysia. The company manufactures an FDA-cleared, CE-marked handheld device that enables primary health workers and clinicians to identify breast lumps in approximately 10 minutes without pain, radiation, or the need for advanced imaging infrastructure. The core product is positioned as a triage and early-detection tool for breast cancer screening in both low-resource settings and mainstream clinical workflows.

The device is built on patented Dynamic Co-Planar Capacitive Sensor technology, invented at Drexel University, which uses an array of tactile sensors to electrically measure subtle tissue displacements under gentle applied force. This functions as quantitative electronic palpation, differentiating hard or stiff tumor tissue from normal breast tissue based on elastic modulus, without requiring user interpretation. The system has been clinically validated across 25,000+ women in multiple independent studies, including a governmental institution study of 18,366 women, with peer-reviewed publications in The Lancet Global Health, Annals of Oncology, JCO Global Oncology, and the World Journal of Surgical Oncology.

iBreastExam generates revenue primarily through hardware sales of the device to healthcare systems, hospitals, medical colleges, and public health agencies. Distribution is conducted via enterprise field sales supplemented by channel partnerships, notably Siemens Healthineers for the US market and a potential joint venture with DASA for Brazil. The company also participates in large-scale government-sponsored screening programs, including a 250,000-women door-to-door campaign in rural India. Customer segments span adult women seeking painless screening, clinicians, government health agencies, and NGO partners such as Rotary Club Hudson Valley. Award recognition includes WHO Innovative Health Technology (2016), the IFC/World Bank Global Women's HealthTech Award (2022), and a Bayer Foundation Grants4Impact award.

Name

iBreastExam

Legal name

UE LifeSciences Inc.

Website

https://ibreastexam.com

Company type

Private

Founded year

2009

Operating status

Operating

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHABAF

Mammography & Breast Imaging Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

• Breast cancer screening
• Medical imaging devices
• Tactile sensor technology
• Women's health diagnostics
• Clinical screening tools

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of iBreastExam handheld devices to healthcare systems, hospitals, clinics, and public health agencies for breast cancer screening programs. The company manufactures and sells the FDA-cleared device directly and through distribution partners like Siemens Healthineers.
2. Large-Scale Screening Programs: Partnerships with public health agencies, NGOs, and government bodies for large-scale breast cancer screening campaigns, particularly in underserved regions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

iBreastExam is an FDA-cleared, CE-marked handheld medical device that uses patented Dynamic Co-Planar Capacitive Sensor technology to detect breast lumps through tactile tissue elasticity measurement. The device enables primary health workers to perform painless, radiation-free breast examinations with results in approximately 10 minutes, intended for clinical settings, public health screening programs, and community outreach campaigns.

Product overview

iBreastExam is a single unified medical device product — a handheld FDA-cleared and CE-marked tactile imaging system designed for early breast lump detection. The device uses patented Dynamic Co-Planar Capacitive Sensor technology, invented at Drexel University, to measure tissue elasticity differences between hard breast tumors and normal tissue in real-time. It is intended for use by primary health workers and clinicians in outpatient settings, offering a quick (approximately 10 minutes), painless, and radiation-free alternative to traditional breast screening methods. The product is distributed through partnerships including Siemens Healthineers and is available in 12 countries across India, Mexico, Malaysia, and the USA.

Differentiator

Problem solved

Functional benefit

Products and services

• iBreastExam FDA-cleared handheld breast examination device that uses Dynamic Co-Planar Capacitive Sensors to detect breast lumps through tactile imaging, enabling early detection without pain or radiation in approximately 10 minutes. Intended for clinicians, primary health workers, and public health screening programs.

Quantifiable outcome

• 2 million+ breast exams enabled in 12 countries
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, minor and flagship.

• Siemens HealthineerscoreChannel Partner/ Reseller/ DistributorSiemens Healthineers partnered with UE LifeSciences for US market launch of iBreastExam. The device is listed on Siemens Healthineers website as part of their accessories portfolio, enabling broad distribution through their established healthcare system relationships.
• PfizerminorStrategic or Co-development PartnerPartnership with Pfizer mentioned alongside Siemens Healthineers on the iBreastExam website. Specific partnership details and announced date not provided.
• Union for International Cancer Control (UICC)coreGTM or Marketing PartnerUE LifeSciences became a partner of UICC, joining the global cancer community. Presented at the 2022 World Cancer Congress. CEO Cary Adams of UICC expressed honor in having UELS join the organization.
• Montefiore Einstein Cancer CentercoreStrategic or Co-development PartnerLeading Cancer Center in New York partnered to bring iBreastExam to women in NY through a campaign with Rotary Club Hudson Valley for breast cancer early detection.
• Rotary Club Hudson ValleycoreGTM or Marketing PartnerPartnership with Rotary Club Hudson Valley and Montefiore Einstein Cancer Center for breast cancer early detection campaign serving women in New York.
• DASAflagshipChannel Partner/ Reseller/ DistributorDASA, the largest diagnostics company in Latin America with 20,000 employees and over 2,000 doctors, is supporting clinical validation for UELS innovations and has keen interest to commercialize UELS products in Brazil under a joint venture.
• Drexel UniversitycoreStrategic or Co-development PartneriBreastExam technology was invented at Drexel University, Philadelphia. Translational research and commercialization supported by Coulter Program at Drexel.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Therapixel: Therapixel provides AI-based mammography decision support (MammoScreen 2.x) with CE mark and FDA pathway for breast cancer detection. Comparable as an AI-powered breast imaging vendor focused on improving early detection accuracy and clinical workflow.
• Kheiron Medical Technologies: Kheiron Medical develops AI-based breast cancer screening software (Mia) that assists radiologists reading mammograms. Comparable as a technology-enabled breast cancer detection company pursuing clinical workflow integration and screening accuracy improvement through novel methods.
• Real Imaging: Real Imaging (Israel) developed the MiraVista system, a 3D functional infrared imaging device for breast cancer detection without radiation or compression. Comparable as a radiation-free, non-mammography breast cancer detection technology pursuing similar safety-focused positioning.
• Niramai HealthAnalytix: Niramai (India-based) developed a non-invasive, radiation-free breast cancer screening solution using thermal imaging and AI, targeting Indian and emerging market screening programs. Highly comparable as a radiation-free, emerging-market-focused breast screening company pursuing similar public health screening contracts.

Direct peers

• iCAD: iCAD provides AI-powered breast cancer detection and workflow solutions for mammography, including ProFound AI for digital breast tomosynthesis. Comparable as a technology-enabled breast cancer detection vendor pursuing similar clinical end-users (radiologists, breast centers) with software/hardware adjunct positioning.
• Volpara Health: Volpara Health provides AI-driven breast imaging analytics for mammography quality, density assessment, and risk evaluation, used by breast centers globally. Comparable as a breast imaging analytics/detection technology vendor targeting early detection workflows and clinical providers.
• Delphinus Medical Technologies: Delphinus developed SoftVue, a 3D whole breast ultrasound tomography system for dense breast tissue screening. Comparable as a non-mammography breast cancer screening technology focused on adjunct detection where mammography has limitations—a similar positioning strategy to iBreastExam.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers manufactures mammography systems and is iBreastExam's US distribution partner. Comparable as both a strategic channel partner and a broad incumbent whose breast imaging portfolio competes for the same hospital procurement budgets.
• Hologic: Hologic is a global leader in women's health imaging, dominating the mammography market with the Selenia Dimensions 3D system and Affirm biopsy guidance. Comparable to iBreastExam as the incumbent standard of care in breast cancer screening that iBreastExam positions as an adjunct or alternative in low-resource settings.
• GE HealthCare: GE HealthCare offers a broad portfolio including mammography (Senographe Pristina), ultrasound, and breast MRI systems with global service infrastructure. Comparable as a broad incumbent in breast imaging whose installed-base relationships iBreastExam must navigate when selling into enterprise accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=kUY9jR7BPDg
• Facebookfacebook.com/strikingly
• Xx.com/ibreastexam

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iBreastExam